CN117598975A - Chitosan gel product and preparation method thereof - Google Patents
Chitosan gel product and preparation method thereof Download PDFInfo
- Publication number
- CN117598975A CN117598975A CN202311574152.8A CN202311574152A CN117598975A CN 117598975 A CN117598975 A CN 117598975A CN 202311574152 A CN202311574152 A CN 202311574152A CN 117598975 A CN117598975 A CN 117598975A
- Authority
- CN
- China
- Prior art keywords
- parts
- chitosan
- gel product
- chitosan gel
- weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229920001661 Chitosan Polymers 0.000 title claims abstract description 99
- 238000002360 preparation method Methods 0.000 title claims abstract description 26
- 238000004519 manufacturing process Methods 0.000 title description 3
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims abstract description 20
- 229960001927 cetylpyridinium chloride Drugs 0.000 claims abstract description 20
- YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 claims abstract description 20
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims abstract description 19
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims abstract description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 19
- 239000002994 raw material Substances 0.000 claims abstract description 18
- 239000008367 deionised water Substances 0.000 claims abstract description 14
- 229910021641 deionized water Inorganic materials 0.000 claims abstract description 14
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 39
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 34
- TXFPEBPIARQUIG-UHFFFAOYSA-N 4'-hydroxyacetophenone Chemical compound CC(=O)C1=CC=C(O)C=C1 TXFPEBPIARQUIG-UHFFFAOYSA-N 0.000 claims description 26
- 229960003333 chlorhexidine gluconate Drugs 0.000 claims description 13
- YZIYKJHYYHPJIB-UUPCJSQJSA-N chlorhexidine gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.C1=CC(Cl)=CC=C1NC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)NC1=CC=C(Cl)C=C1 YZIYKJHYYHPJIB-UUPCJSQJSA-N 0.000 claims description 13
- 235000011187 glycerol Nutrition 0.000 claims description 13
- ACCCMOQWYVYDOT-UHFFFAOYSA-N hexane-1,1-diol Chemical compound CCCCCC(O)O ACCCMOQWYVYDOT-UHFFFAOYSA-N 0.000 claims description 11
- 229920000936 Agarose Polymers 0.000 claims description 6
- SVTBMSDMJJWYQN-UHFFFAOYSA-N 2-methylpentane-2,4-diol Chemical compound CC(O)CC(C)(C)O SVTBMSDMJJWYQN-UHFFFAOYSA-N 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 3
- 229940051250 hexylene glycol Drugs 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims description 2
- 230000000844 anti-bacterial effect Effects 0.000 abstract description 22
- 230000008859 change Effects 0.000 abstract description 11
- 230000005855 radiation Effects 0.000 abstract description 3
- 230000008901 benefit Effects 0.000 abstract description 2
- 230000000087 stabilizing effect Effects 0.000 abstract description 2
- 239000000047 product Substances 0.000 description 45
- 239000000499 gel Substances 0.000 description 38
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 14
- 239000000126 substance Substances 0.000 description 9
- 230000000694 effects Effects 0.000 description 8
- 235000012000 cholesterol Nutrition 0.000 description 7
- 210000002421 cell wall Anatomy 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 206010020772 Hypertension Diseases 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 230000001804 emulsifying effect Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 238000012803 optimization experiment Methods 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 150000004676 glycans Chemical class 0.000 description 3
- 229910052753 mercury Inorganic materials 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 238000001179 sorption measurement Methods 0.000 description 3
- 208000013464 vaginal disease Diseases 0.000 description 3
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 2
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 2
- 229920002101 Chitin Polymers 0.000 description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
- JPVYNHNXODAKFH-UHFFFAOYSA-N Cu2+ Chemical compound [Cu+2] JPVYNHNXODAKFH-UHFFFAOYSA-N 0.000 description 2
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 2
- 239000003613 bile acid Substances 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 229910052802 copper Inorganic materials 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- 229910001431 copper ion Inorganic materials 0.000 description 2
- 238000007599 discharging Methods 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 229920001002 functional polymer Polymers 0.000 description 2
- 229960002442 glucosamine Drugs 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 229910001385 heavy metal Inorganic materials 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- -1 mercury ions Chemical class 0.000 description 2
- 229910021645 metal ion Inorganic materials 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 238000000554 physical therapy Methods 0.000 description 2
- 238000004382 potting Methods 0.000 description 2
- 235000013772 propylene glycol Nutrition 0.000 description 2
- 239000011265 semifinished product Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 1
- 102000005862 Angiotensin II Human genes 0.000 description 1
- 101800000733 Angiotensin-2 Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 208000008763 Mercury poisoning Diseases 0.000 description 1
- 206010027439 Metal poisoning Diseases 0.000 description 1
- 240000000249 Morus alba Species 0.000 description 1
- 235000008708 Morus alba Nutrition 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 1
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 1
- 208000005374 Poisoning Diseases 0.000 description 1
- 241000224526 Trichomonas Species 0.000 description 1
- 229910052770 Uranium Inorganic materials 0.000 description 1
- 206010047139 Vasoconstriction Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 229950006323 angiotensin ii Drugs 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 210000005056 cell body Anatomy 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000006196 deacetylation Effects 0.000 description 1
- 238000003381 deacetylation reaction Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000001278 effect on cholesterol Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 229920005615 natural polymer Polymers 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 229920006254 polymer film Polymers 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 239000004753 textile Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- JFALSRSLKYAFGM-UHFFFAOYSA-N uranium(0) Chemical compound [U] JFALSRSLKYAFGM-UHFFFAOYSA-N 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4425—Pyridinium derivatives, e.g. pralidoxime, pyridostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/722—Chitin, chitosan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a chitosan gel product and a preparation method thereof, wherein the preparation raw materials of the chitosan gel product comprise the following components in parts by weight: 2-8 parts of chitosan, 0.5-2 parts of hydroxyethyl cellulose, 0.05-0.2 part of cetylpyridinium chloride and 50-90 parts of deionized water. The chitosan gel product provided by the invention has the advantages that the physicochemical comparison before and after irradiation is carried out, the PH value change is small, the viscosity is obviously reduced along with the increase of the irradiation dose, the antibacterial rate is obviously improved, and the radiation resistance is excellent; in the chitosan gel product, HEC is added to have a stabilizing effect on the viscosity of the product, and CPC is added to improve the antibacterial rate; the chitosan gel product of the invention has simple preparation process, low cost and good market application prospect.
Description
Technical Field
The invention relates to the field of antibacterial materials, in particular to a chitosan gel product and a preparation method thereof.
Background
Chitosan, also known as deacetylated chitin, is the only natural alkaline polysaccharide found so far, and has abundant reserves in nature and is produced by a large number of factories. The chitosan is named as follows: (1, 4) -2-amino-2-deoxy-beta-D-glucose as a white amorphous, translucent, slightly pearlescent solid [1] . In the 60 s of the nineteenth century, rouset (forensic) first discovered this basic polysaccharide, and later in the continuous research of the latter, found that this natural polymer polysaccharide has excellent biofunctionality, biocompatibility, biosafety, and is easily degraded by microorganisms, so that it was widely used in the fields of medicine, food, chemical industry, cosmetics, water treatment, metal extraction and recovery, biochemistry, biomedical engineering, and the like.
The main antibacterial mechanisms of the antibacterial agents in the market are as follows: 1. piercing the cell wall, disrupting the cell wall, 2 disrupting the breakdown and anabolic pathways of the microorganism, thereby disrupting the breakdown and synthesis of the microorganism, 3 altering the permeability of the cell membrane, inactivating it, such as enzymes, proteins, nucleic acid molecules, and the like. The molecular composition of chitosan is characterized in that firstly, glucosamine monomers are combined with each other through hydrogen bonds, and are polymerized by the monomers, wherein part of the chitosan is glucose containing acetamido; and secondly, glucosamine is a substance with stronger positive charges in the structure, and can adsorb substances with negative charges. Thus the antibacterial mechanism of chitosan is more complex [2] . The antibacterial mechanism of chitosan is not yet known in the academia, and the following 2 mechanisms are currently considered: one is that the-NH+3-NH3+ in chitosan molecule is positively charged and adsorbed on the cell surface, on one hand, a layer of polymer film can be formed to prevent nutrient substances from being transported into the cell, on the other hand, the negative charges on the cell wall and the cell membrane are unevenly distributed, the synthesis and dissolution balance of the cell wall are destroyed, and the cell wall is dissolved, so that the antibacterial and bactericidal effects are realized; the other is to permeate into cells to adsorb substances with anions in the cell bodies and disturb the normal physiological activities of the cells so as to kill bacteria [3] . For both reasons, it is thought that this occurs between the long alkyl chain, which is hydrophobic, and the phospholipids on the bacterial cytoplasmic membraneHydrophobic affinity breaks down the bacterial cytoplasmic membrane, thereby creating antimicrobial properties [4] . Young et al [5] Chitosan is considered to act as a target for microbial cells
Chitosan has mainly the following known biological properties:
(1) Control of cholesterol
Cholesterol is one of the biggest problems in human health, which leads to a number of serious diseases. Chitosan can be low in cholesterol and has two mechanisms: one is to prevent the human body from absorbing fat, and the other is to excrete cholesterol in the human body blood. First, chitosan has the ability to inhibit the activity of human lipase, thereby impeding the conversion and absorption of fatty substances. Another chitosan contributes to bile acid in the blood where it is excreted, and bile acid is cholesterol production, so that the effect of reducing the amount of cholesterol in the blood is indirectly achieved. So chitosan is said to be a powerful cholesterol scavenger. In addition, chitosan has no side effect on cholesterol reduction.
(2) Inhibition of bacterial activity
Chitosan is easy to dissolve in weak acid environment, and NH2 is released after dissolution + Ions of these NH 2' s + The ions inhibit the growth of bacteria by combining with negative electrons, so that a good antibacterial effect is achieved. The chitosan has a good antibacterial effect, and has wide application in the fields of food, medicine, textile and the like.
(3) Preventing and controlling hypertension
The human being eats the salt every day, but the Cl in the salt - But also can easily cause hypertension, especially for those people who take excessive salt. Vascular CL - Excessive human body produces excessive angiotensin converting enzyme, which in turn produces more angiotensin II, causing vasoconstriction and hypertension. The high molecular chitosan passes through NH2 of the high molecular chitosan + Adsorption of Cl - Then excrete Cl - Thereby reducing Cl - The content of (3) can achieve the effects of reducing blood pressure, preventing and controlling hypertension.
(4) Adsorption and excretion of heavy metals
The adsorption capacity of chitosan is also effective for metal ions such as organic mercury, copper, magnesium and uranium. Some metal ions are harmful to the human body. Such as copper ions (cu2+) or mercury ions (hg2+), if the concentration of copper ions (cu2+) or mercury ions (hg2+) in the blood is too high, copper poisoning or mercury poisoning may occur, and even carcinogenic or death consequences may occur. Chitosan has proven to be a highly efficient heavy metal chelate. Particularly, chitosan with high deacetylation degree has stronger chelating ability.
(5) Immune effect
The chitosan has the capability of stimulating and increasing immune cells, thereby improving the immune function of the organism and enhancing the anti-infection capability. Therefore, the chitosan can be used for improving the immunity of organisms and has a certain effect on the prevention and treatment of some infectious diseases.
Although the physical therapy adopted in the treatment of the gynecological diseases can achieve a certain curative effect, the physical therapy can cause different degrees of injury to the organism and influence the normal life of patients. The chitosan has the functions of resisting bacteria, resisting tumors, enhancing immunity and the like, has good biocompatibility, has no irritation and toxic or side effect, has good treatment effect on treating gynecological diseases such as bacterial vagina diseases, candidal vagina diseases, trichomonas vagina diseases, cervical erosion and the like, but the chitosan product has less research on radiation resistance, and the radiation-resistant chitosan product is rarely disclosed.
Reference is made to:
[1] wang Yuting, liu Yugong, zhang Shuqin. Chemical modification of chitin/chitosan and research progress for its use as derivatives [ J ]. Functional Polymer journal, 2002,15 (1): 107.
[2] Liu Biyuan and Gao Shiying journal of Chinese Biochemical medicine [ J ] functional Polymer journal, 2004,24 (5): 268-270.
[3] Xia Jinlan, wangchun, liu Xinxing. Antibacterial agent and antibacterial mechanism [ J ]. University of south and middle school, 2004,35 (1): 36.
[4] Jiang Xia, xu Ming, zhang Li application prospect of chitosan derivatives in feed industry [ J ]. Shanghai livestock veterinary communication, 2008 (1): 69-71.
[5]Young,D.H.KNole,H.E.and Kauss,H.E.(1983)Release of Calcium from Suspension-Cultured Glycine Max Cells by Chitosan[J].Plant Physiology,1983(3):698-702.
[6] Cui Wenhui, guo Qin, li Qingpeng, etc. the structure and properties of chitosan acylation modified products at different irradiation doses are compared to those of modern food technology [ J ], [ 2016,032 (006) ] 77-84.
Disclosure of Invention
The technical problem to be solved by the invention is to provide a chitosan gel product and a preparation method thereof aiming at the defects in the prior art.
In order to solve the technical problems, the invention adopts the following technical scheme: the chitosan gel product is characterized in that the preparation raw materials comprise chitosan, hydroxyethyl cellulose, cetylpyridinium chloride and deionized water.
Preferably, the chitosan gel product is prepared from the following raw materials in parts by weight: 2-8 parts of chitosan, 0.5-2 parts of hydroxyethyl cellulose, 0.05-0.2 part of cetylpyridinium chloride and 50-90 parts of deionized water.
Preferably, 0.075 to 0.3 parts by weight of agarose is also included.
Preferably, 7.5 to 30 parts by weight of glycerin are also included.
Preferably, 1.5 to 6 parts by weight of propylene glycol is also included.
Preferably, the catalyst further comprises 0.25 to 1 part by weight of p-hydroxyacetophenone.
Preferably, 0.25 to 1 part by weight of hexanediol is also included.
Preferably, the composition further comprises 0.125-0.5 parts by weight of chlorhexidine gluconate.
Preferably, the chitosan gel product is prepared from the following raw materials in parts by weight: 3.5 parts of chitosan, 1 part of hydroxyethyl cellulose, 0.1 part of cetylpyridinium chloride, 76.25 parts of deionized water, 15 parts of glycerin, 3 parts of propylene glycol, 0.5 part of p-hydroxyacetophenone, 0.5 part of hexanediol and 0.25 part of chlorhexidine gluconate.
The invention also provides a preparation method of the chitosan gel product, which comprises the following steps: and uniformly mixing the preparation raw materials according to the weight portion ratio to obtain the chitosan gel product.
The beneficial effects of the invention are as follows:
the invention provides a chitosan gel product and a preparation method thereof, wherein the chitosan gel product has the advantages of physicochemical comparison before and after irradiation, small PH value change, obvious viscosity reduction and obviously improved antibacterial rate along with the increase of irradiation dose, and excellent irradiation resistance; in the chitosan gel product, HEC is added to have a stabilizing effect on the viscosity of the product, and CPC is added to improve the antibacterial rate; the chitosan gel product of the invention has simple preparation process and lower cost, can be used for treating gynecological diseases or preparing related medicines for treating gynecological diseases, and has good market application prospect.
Drawings
FIG. 1 shows the pH change before and after irradiation of the chitosan gel product prepared in the example;
FIG. 2 is a graph showing the results of the change in viscosity values before and after irradiation of the chitosan gel product prepared in the example;
FIG. 3 shows the results of the change in the antibacterial rate of the chitosan gel product prepared in the example before and after irradiation.
Detailed Description
The present invention is described in further detail below with reference to examples to enable those skilled in the art to practice the same by referring to the description.
It will be understood that terms, such as "having," "including," and "comprising," as used herein, do not preclude the presence or addition of one or more other elements or groups thereof.
The test methods used in the following examples are conventional methods unless otherwise specified. The material reagents and the like used in the following examples are commercially available unless otherwise specified. The following examples were conducted under conventional conditions or conditions recommended by the manufacturer, without specifying the specific conditions. The reagents or apparatus used were conventional products commercially available without the manufacturer's attention.
The invention provides a chitosan gel product, which is prepared from the following raw materials of chitosan, hydroxyethyl cellulose (HEC), cetylpyridinium chloride (CPC) and deionized water.
In a preferred embodiment, the preparation raw materials comprise the following components in parts by weight: 2-8 parts of chitosan, 0.5-2 parts of hydroxyethyl cellulose, 0.05-0.2 part of cetylpyridinium chloride and 50-90 parts of deionized water.
In a preferred embodiment, 0.075 to 0.3 parts by weight agarose is also included.
In a preferred embodiment, 7.5 to 30 parts by weight of glycerol are also included.
In a preferred embodiment, 1.5 to 6 parts by weight of propylene glycol is also included.
In a preferred embodiment, 0.25 to 1 parts by weight of p-hydroxyacetophenone is also included.
In a preferred embodiment, 0.25 to 1 parts by weight of hexanediol is also included.
In a preferred embodiment, chlorhexidine gluconate is also included in an amount of 0.125 to 0.5 parts by weight.
In a preferred embodiment, the chitosan gel product is prepared from the following raw materials in parts by weight: 3.5 parts of chitosan, 1 part of hydroxyethyl cellulose, 0.1 part of cetylpyridinium chloride, 76.25 parts of deionized water, 15 parts of glycerin, 3 parts of propylene glycol, 0.5 part of p-hydroxyacetophenone, 0.5 part of hexanediol and 0.25 part of chlorhexidine gluconate.
The invention also provides a preparation method of the chitosan gel product, which comprises the following steps: weighing the components according to the weight, dissolving p-hydroxyacetophenone, hexanediol and CPC with a proper amount of water to obtain a pretreatment liquid, adding chitosan, HEC, glycerol and propylene glycol into an emulsifying pot for uniform dispersion, adding the rest water into the emulsifying pot, and heating to 90-95 ℃; and (3) cooling after stirring and dissolving, cooling to 45-40 ℃, adding the pretreatment liquid and chlorhexidine gluconate, stirring until the solution is completely dissolved, discharging, filling after the semi-finished product is detected to be qualified, packaging, and warehousing after the finished product is detected to be qualified, thus obtaining the chitosan gel product.
The foregoing is a general inventive concept and the following detailed examples are provided to further illustrate the invention.
Description of the sources of the reagents
Chitosan (tsaoko cloud biotechnology limited), gelatin (national pharmaceutical community chemical reagent limited), agarose (Lonza Ltd), glycerol (Natural Oleochemicals Sdn Bhd), propylene glycol (middle sea shell petrochemical limited), p-hydroxyacetophenone (Shanghai Yiming chemical technology limited), hexylene glycol (light (Shanghai) chemical industry trade limited), chlorhexidine gluconate (siean Fang chemical limited), HEC (asia blue division), CPC (beijing mulberry biochemistry limited).
Recipe optimization experiment
According to the invention, after investigation of the data such as the prior bid information, the literature records and the like, a plurality of different formula combinations are selected, and the optimal formula with good treatment effect, convenient use, simple preparation process and low cost is screened from the viscosity, the PH value and the antibacterial rate before and after irradiation.
Initial optimization experiment
According to the formulas (in parts by weight) shown in the following tables 1 and 2, the raw materials were uniformly mixed to prepare samples, and then the viscosity value, the pH value and the antibacterial rate of the samples before and after irradiation (6-10K) were measured.
TABLE 1
TABLE 2
The following conclusions are drawn according to the experimental results:
(1) The viscosity of the chitosan gel product is reduced after irradiation;
(2) The antibacterial rate of the chitosan gel product after irradiation is improved;
(3) The PH value of the chitosan gel product is not changed greatly after irradiation;
(4) The chitosan gel products turn yellow after being irradiated;
(5) The chitosan gel product is not added with other bacteriostats, the bacteriostasis rate does not reach the standard, and other bacteriostats must be matched;
(6) The viscosity of the HEC is stable before and after the chitosan gel product is irradiated;
(7) The antibacterial rate of the chitosan gel product added with CPC is obviously improved.
Re-optimization experiment
According to the formula of the following table 3 (the unit is weight part in the table), the raw materials are uniformly mixed to prepare a sample, and then the viscosity value, the PH value and the antibacterial rate of the sample before and after irradiation (6-10K, 10-20K and 20-30K) are detected.
TABLE 3 Table 3
The following conclusions are drawn according to the experimental results:
(1) The viscosity of the chitosan gel product is reduced after irradiation, and the reduction is more obvious along with the increase of the irradiation dose;
(2) The antibacterial rate of the chitosan gel product after irradiation is obviously improved;
(3) The PH value of the chitosan gel product is not changed greatly after irradiation;
(4) The chitosan gel products all turn yellow after irradiation, and the color change is more obvious when the dosage is larger.
According to the above optimization experiment results, the following examples of 4 preferred formulations are provided, and the preferred formulations are obtained according to the detection results.
Example 1
The chitosan gel product comprises the following preparation raw materials in parts by weight: 4 parts of chitosan, 0.1 part of cetylpyridinium chloride, 76.6 parts of deionized water, 0.15 part of agarose, 15 parts of glycerol, 3 parts of propylene glycol, 0.5 part of p-hydroxyacetophenone, 0.5 part of hexanediol and 0.25 part of chlorhexidine gluconate.
The preparation method comprises the following steps: weighing the components according to the weight, dissolving p-hydroxyacetophenone, hexanediol and CPC with a proper amount of water to obtain a pretreatment liquid, adding chitosan, HEC, glycerol and propylene glycol into an emulsifying pot for uniform dispersion, adding the rest water into the emulsifying pot, and heating to 90-95 ℃; and (3) cooling after stirring and dissolving, cooling to 45-40 ℃, adding the pretreatment liquid and chlorhexidine gluconate, stirring until the solution is completely dissolved, discharging, filling after the semi-finished product is detected to be qualified, packaging, and warehousing after the finished product is detected to be qualified, thus obtaining the chitosan gel product.
Example 2
The chitosan gel product comprises the following preparation raw materials in parts by weight: 3.5 parts of chitosan, 1 part of hydroxyethyl cellulose, 0.1 part of cetylpyridinium chloride, 76.1 parts of deionized water, 0.15 part of agarose, 15 parts of glycerol, 3 parts of propylene glycol, 0.5 part of p-hydroxyacetophenone, 0.5 part of hexanediol and 0.25 part of chlorhexidine gluconate.
The preparation method is the same as in example 1.
Example 3
The chitosan gel product comprises the following preparation raw materials in parts by weight: 4 parts of chitosan, 1.2 parts of hydroxyethyl cellulose, 0.1 part of cetylpyridinium chloride, 75.55 parts of deionized water, 15 parts of glycerol, 3 parts of propylene glycol, 0.5 part of p-hydroxyacetophenone, 0.5 part of hexanediol and 0.25 part of chlorhexidine gluconate.
The preparation method is the same as in example 1.
Example 4
The chitosan gel product comprises the following preparation raw materials in parts by weight: 3.5 parts of chitosan, 1 part of hydroxyethyl cellulose, 0.1 part of cetylpyridinium chloride, 76.25 parts of deionized water, 15 parts of glycerin, 3 parts of propylene glycol, 0.5 part of p-hydroxyacetophenone, 0.5 part of hexanediol and 0.25 part of chlorhexidine gluconate.
The preparation method is the same as in example 1.
The formulations of examples 1-4 are shown in Table 1 below (in parts by weight):
TABLE 1
Detecting the viscosity value, the PH value and the antibacterial rate of the products prepared in examples 1-4 before and after irradiation; irradiation conditions: 6-10K, 10-20K and 20-30K. The pH value change results before and after irradiation are shown in FIG. 1, the viscosity value change results are shown in FIG. 2, the bacteriostasis rate change results are shown in FIG. 3, and the abscissas 1, 2, 3 and 4 in FIGS. 1-3 represent examples 1, 2, 3 and 4.
As can be seen from the results of the test,
overall, the method comprises the following steps: (1) The viscosity of the chitosan gel product is reduced after irradiation, and the reduction is more obvious along with the increase of the irradiation dose; (2) The antibacterial rate of the chitosan gel product after irradiation is obviously improved; (3) the PH value of the chitosan gel product does not change greatly after irradiation.
The chitosan gel product of example 4 showed less PH change as compared to the front and back physicochemical; the viscosity is obviously reduced along with the increase of the irradiation dose; the antibacterial rate is obviously improved, and the formula is a better choice.
Although embodiments of the present invention have been disclosed above, it is not limited to the use of the description and embodiments, it is well suited to various fields of use for the invention, and further modifications may be readily apparent to those skilled in the art, and accordingly, the invention is not limited to the particular details without departing from the general concepts defined in the claims and the equivalents thereof.
Claims (10)
1. The chitosan gel product is characterized in that the preparation raw materials comprise chitosan, hydroxyethyl cellulose, cetylpyridinium chloride and deionized water.
2. The chitosan gel product according to claim 1, wherein the preparation raw materials thereof comprise, in parts by weight: 2-8 parts of chitosan, 0.5-2 parts of hydroxyethyl cellulose, 0.05-0.2 part of cetylpyridinium chloride and 50-90 parts of deionized water.
3. The chitosan gel product according to claim 2, further comprising 0.075-0.3 parts by weight agarose.
4. A chitosan gel product according to claim 3, further comprising 7.5-30 parts by weight of glycerol.
5. The chitosan gel product according to claim 4, further comprising 1.5-6 parts by weight of propylene glycol.
6. The chitosan gel product according to claim 5, further comprising 0.25-1 parts by weight of p-hydroxyacetophenone.
7. The chitosan gel product according to claim 6, further comprising 0.25-1 parts by weight of hexylene glycol.
8. The chitosan gel product of claim 7, further comprising 0.125-0.5 parts by weight of chlorhexidine gluconate.
9. The chitosan gel product according to claim 8, wherein the preparation raw materials thereof comprise, in parts by weight: 3.5 parts of chitosan, 1 part of hydroxyethyl cellulose, 0.1 part of cetylpyridinium chloride, 76.25 parts of deionized water, 15 parts of glycerin, 3 parts of propylene glycol, 0.5 part of p-hydroxyacetophenone, 0.5 part of hexanediol and 0.25 part of chlorhexidine gluconate.
10. A method of preparing a chitosan gel product according to any one of claims 1-9, characterized in that the method comprises: and uniformly mixing the preparation raw materials according to the weight portion ratio to obtain the chitosan gel product.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311574152.8A CN117598975A (en) | 2023-11-23 | 2023-11-23 | Chitosan gel product and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311574152.8A CN117598975A (en) | 2023-11-23 | 2023-11-23 | Chitosan gel product and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN117598975A true CN117598975A (en) | 2024-02-27 |
Family
ID=89943609
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202311574152.8A Pending CN117598975A (en) | 2023-11-23 | 2023-11-23 | Chitosan gel product and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN117598975A (en) |
-
2023
- 2023-11-23 CN CN202311574152.8A patent/CN117598975A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Raj et al. | Grafting modification of okra mucilage: Recent findings, applications, and future directions | |
| CN106727432A (en) | A kind of Prussian blue analogue nano particle and preparation method and application | |
| CN108310392B (en) | Preparation method of medical graphene oxide antibacterial agent | |
| CN110903488A (en) | Preparation method of chitosan @ metal organic framework antibacterial material | |
| Peng et al. | Bimetal metal–organic framework domino micro-reactor for synergistic antibacterial starvation/chemodynamic therapy and robust wound healing | |
| CN103040730A (en) | Iron sucrose injection and preparation method thereof | |
| CN113069591A (en) | Chitosan-calcium polyglutamate biological dressing and preparation method thereof | |
| CN105084475A (en) | Disinfection effervescent tablet with water quality purification effect and preparation method of disinfection effervescent tablet | |
| CN102405935B (en) | Protamine compounded preparation, preparation method and application thereof | |
| CN105860103A (en) | Preparation method and application of novel nano hydrogel | |
| CN104706580A (en) | Veterinary interferon inducer and preparation method thereof | |
| CN117598975A (en) | Chitosan gel product and preparation method thereof | |
| CN103951732B (en) | A kind of antibacterial peptide | |
| CN106943346A (en) | Metildigoxin liquid preparation, Its Preparation Method And Use | |
| CN111529549B (en) | Antibacterial and antiviral high-valence electrolytic silver ion solution and preparation method thereof | |
| CN106474053B (en) | A kind of composite high-molecular colloid surface of a wound thimerosal and its preparation method containing amino acid | |
| CN110237263B (en) | HFn method for entrapping adriamycin and product thereof | |
| CN103239392B (en) | Ornidazole injection preparation and preparation method | |
| RU2460532C1 (en) | Preparation fastening wound healing | |
| CN103561735B (en) | There is the pharmaceutical preparation of antibacterial, antiulcer and immunoregulation effect | |
| CN110354390A (en) | A kind of diabetes Wound healing preparation and its application | |
| CN1840184A (en) | Lysozyme liposome and preparation method thereof | |
| RU2752169C1 (en) | Pharmaceutical based on compound of antimony with biocompatible matrix | |
| CN108042801B (en) | Toluidine blue efficient photodynamic sterilization composition and application thereof | |
| CN112915257B (en) | Preparation method of sterilized cellulose gel |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |